

# Anti-Toxoplasma gondii [POLYCLONAL]

Catalog No.	Description
AR125-5RE	6 ml of Ready-to-Use Antibody for use with BioGenex Super Sensitive <sup>TM</sup> Detection Systems OR equivalent detection system
AR125-10RE	10 ml of Ready-to-Use Antibody for use with BioGenex Super Sensitive <sup>TM</sup> Detection Systems OR equivalent detection system
PU125-UPE	1 ml of Concentrated Antibody for use with BioGenex Super Sensitive <sup>TM</sup> Detection Systems OR equivalent detection system
PU125-5UPE	0.5 ml of Concentrated Antibody for use with BioGenex Super Sensitive <sup>TM</sup> Detection Systems OR equivalent detection system
AW125- YCDE	Ready-to-Use Antibody in Barcode labeled vial for use on the Xmatrx® Elite Staining System, 160 tests
AW125- 50DE	Ready-to-Use Antibody in Barcode labeled vial for use on the Xmatrx <sup>®</sup> Elite Staining System, 50 tests

Clone	Species	Ig Class
Polyclonal	Rabbit	N/A

#### **Intended Use**

For Research Use. This antibody is designed for the specific localization of Toxoplasma gondii in formalin-fixed, paraffinembedded (FFPE) tissue sections. Evaluation must be performed by a qualified pathologist.

#### **Summary and Explanation**

Toxoplasma gondii is a common protozoan parasite of humans and vertebrae animals. In human hosts with a competent immune sytem, T, gondii infection generally develops intio an asymptomatic chronic infection, with the orgaism sequestered in dormant "tissue cysts" often for the lifetime of the host. However in immunocompromised hosts, such as AIDS patients or organ transplant recipients receiving immunosuppressive therapy, infection can lead to toxoplasmosis. The disease is characterized by the proliferation of T. gondii tachyzoites which can damage the central nervous sytem, and can be fatal it untreated.

#### **Storage and Handling**

**Store at 2-8°C.** Fresh dilutions, if required, should be prepared prior to use and are stable and steady for up to one day at room temperature (20-26°C). Diluted antibody preparations can be refrigerated or frozen for extended shelf life.

Antigen detection by immunohistochemistry (IHC) is a two-step process wherein the primary antibody binds to the antigen of interest and that binding is detected by a chromogen. The primary antibody may be used in IHC using manual techniques or BioGenex Automated Staining System. Positive and negative controls should always be run simultaneously with all patient specimens.

# **Reagents Provided**

Rabbit Polyclonal Antibody Toxoplasma gondii is affinity purified and diluted in PBS, pH 7.2, containing 1% BSA and 0.09% sodium azide.

# **Dilution of Primary Antibody**

BioGenex Ready-to-Use antibodies have been optimized for use with the recommended BioGenex Detection System and should not require further dilution.

BioGenex concentrated antibodies must be diluted in accordance with the recommended protocol when used with the recommended BioGenex Detection System.

#### **Recommended Protocol**

Refer to the following table for conditions specifically recommended for this antibody. Refer to the BioGenex website for guidance on specific staining protocols or other requirements.

Parameter	BioGenex Recommendations
Control Tissue	Toxoplasma Infected Tissue as available with Biogenex FG-125PE*
Recommended Dilution for Concentrated Antibody	1:30-50 in HK156-5K
Recommended Pretreatment (Manual/i6000)**	EZ-AR2 (HK522-XAK)
Antibody Incubation (Manual/i6000)	30-60 Min at RT
Detection System for Manual, Xmatrx & i6000 systems***	Use BioGenex Two-Step <b>OR</b> One-Step Super Sensitive <sup>™</sup> Polymer-HRP IHC Detection System/DAB; see p. 2 for more information

<sup>\*</sup>FB: positive control micro chamber slides, FG: positive control microscopicslides. Xmatrx requires micro chamber slides.

# **Principles of the Procedure**

Category	Antibodies	Revision No.	K
Document No.	932-125PE	Release Date	18-Feb-2022

<sup>\*\*</sup>Pretreatment times will vary based on individual microwave power.

\*\*\*For automation systems (Xmatrx-Elite, Xmatrx-Ultra & i6000 Diagnostics), refer to the factory protocols provided with the instrument.



Detection System	Two-Step HRP Kit	One-Step HRP Kit	Link and Label Kit
Manual	QD440- XAKEN (1000 Test) QD430- XAKEN (1000 Test)	QD630- XAKEN (1000 Test)	QP300-XAKE (1000 Test)
Manuai	QD420- YIKEN (500 Test) QD400- 60KEN (60 Test)	QD620- XAKEN (500 Test)	QP900-9LE (500 Test)
i6000 - Automation	QD410- YAXEN (200 Test)	QD610- YAXEN (200 Test)	N/A
For more information, visit <u>www.biogenex.com</u> .			

#### **Precautions**

This product contains sodium azide at concentrations of less than 0.1%. Sodium azide is not classified as a hazardous chemical at the product concentrations, but proper handling protocols should be observed. For more information, a Safety Data Sheet (SDS) for sodium azide is available upon request. Dispose of unused reagents according to Local, State and Federal Regulations. Wear suitable Personal Protective Equipment, do not pipette reagents by mouth, and avoid contact of reagents and specimens with skin and mucous membranes. If reagents or specimens come in contact with sensitive area, wash with copious amounts of water.

## **Quality Control**

Refer to BioGenex detection system documents for guidance on general quality control procedures.

# **Troubleshooting**

Refer to the troubleshooting section in the documentation for BioGenex Detection Systems (or equivalent detection systems) for remedial actions on detection system related issues, or contact BioGenex Technical Support Department at 1-800-421-4149 or <a href="mailto:support@biogenex.com">support@biogenex.com</a> or your local distributor to report unusual staining.

### **Expected Results**

This antibody stains Toxoplasma organisms in positive cells in formalin-fixed, paraffin embedded tissue sections. An example image of a tissue section stained with this antibody can be found on the product page on the BioGenex website. Interpretation of the staining result is solely the responsibility of the user. Experimental results should be confirmed by a medically-established diagnostic product or procedure.

#### **Limitations of the Procedure**

Improper tissue handling and processing prior to immunostaining can lead to inconsistent results. Variations in embedding and fixation or the nature of the tissue may lead to variations in results. Endogenous peroxidase activity or pseudo peroxidase activity in erythrocytes and tissue biotin may result in non-specific staining based on the detection system employed. Tissues containing Hepatitis B Surface Antigen (HBsAg) may give false positive with horseradish peroxidase systems. Improper counterstaining and mounting may compromise the interpretation of results.

# **Bibliography**

- Remington JS, and Desmonts, G.,, In Infectious Diseases of the Fetus and Newborn Infant, Reminton, JS, and Klein, JO, eds, pp. 89-195, WB Saunders, Philadelphia, 1990.
- 2. Conley FK, et al, Hum Pathol 12:690-698. 1981.

2°C 8°C	Temperature Limitation	LOT	Batch Code
$\boxtimes$	Use By Date	i	Consult Instructions for Use
NON STERILE	Non-Sterile	***	Manufacturer

© 2020, BioGenex Laboratories. All rights reserved.

Category	Antibodies	Revision No.	K
Document No.	932-125PE	Release Date	18-Feb-2022